
MicroAlgo Inc. Integrates Quantum Image LSQb Algorithm with Quantum Encryption Technology to Build a More Secure Quantum Information Hiding and Transmission System
By GlobeNewswire Published on June 9, 2025, 18:30 IST
shenzhen, June 09, 2025 (GLOBE NEWSWIRE) — MicroAlgo Inc. Integrates Quantum Image LSQb Algorithm with Quantum Encryption Technology to Build a More Secure Quantum Information Hiding and Transmission System
Shenzhen, Jun. 09, 2025––MicroAlgo Inc. (the 'Company' or 'MicroAlgo') (NASDAQ: MLGO), today announced that by integrating the quantum image LSQb algorithm with quantum encryption technology, they have proposed a brand-new information hiding and transmission scheme, aiming to build a more secure and efficient data protection mechanism.The LSQb algorithm, namely the Least Significant Quantum Bit algorithm for quantum images, is an innovative quantum image processing technology. It achieves secure information hiding by embedding secret information into the least significant quantum bits of a quantum image. Building on this foundation, MicroAlgo further integrates relevant theories from quantum information theory and cryptography, comprehensively expanding the application scope and functionality of the LSQb algorithm. This integration not only enhances the security of information hiding but also improves the efficiency and reliability of information transmission in quantum networks.The core of MicroAlgo's technological innovation lies in utilizing the Least Significant Quantum Bit (LSQb) algorithm for efficient information encoding and decoding, combined with quantum encryption technologies such as Quantum Key Distribution (QKD) to ensure data security during transmission. The LSQb algorithm can identify and select key quantum bits critical to image representation, reducing the number of quantum gate operations by optimizing the embedding and extraction processes, thereby lowering algorithm complexity. Meanwhile, quantum encryption technology provides unconditional security for information transmission, ensuring that information leakage is prevented even in a quantum computing environment.Original Image Preprocessing: First, the original image undergoes compressed sensing and sparse representation to extract key features and convert them into quantum bit form. Further analysis is conducted using machine learning or deep learning models to ensure the retention of important visual elements of the image, reduce the amount of encoded information, and lower algorithm complexity.Quantum Bit Selection and Embedding: An improved Least Significant Quantum Bit (LSQb) algorithm is employed to embed selected key quantum bits into quantum states. Each quantum bit generates a corresponding quantum state and is embedded into a larger quantum state structure through quantum gate operations. Quantum error correction codes and quantum entanglement properties are introduced to enhance the system's robustness and stability, reducing unnecessary quantum gate operations.Quantum Key Distribution and Encryption: Quantum Key Distribution (QKD) technology is utilized to generate a shared key, ensuring the security of data transmission. The sender and receiver exchange correlated quantum states to generate the key, and any attempt to read the states will alter them and be detected, preventing information leakage.Information Transmission and Protection: The encrypted quantum state information is transmitted through a quantum channel, and even if eavesdropping occurs, attackers cannot obtain useful information. By combining protocols such as quantum teleportation, the system's security and flexibility are further enhanced.Information Decryption and Recovery: The receiver uses the shared key to decrypt the quantum state information and applies inverse quantum gate operations to restore the original quantum bit sequence. Key feature information is extracted through a decoding algorithm and reassembled into a complete image, with error correction mechanisms introduced to ensure high-fidelity recovery. The entire process validates the effectiveness and accuracy of information hiding and transmission, establishing an efficient and secure quantum information processing system.MicroAlgo integrates the Least Significant Quantum Bit (LSQb) algorithm for quantum images with other related theories, such as quantum information theory and cryptography, to further expand its application scope and functionality. Combined with quantum encryption technology, it constructs a more secure quantum information hiding and transmission system, ensuring the secure transmission of information in quantum networks. On one hand, it significantly reduces the demand for quantum resources, minimizing the involvement of unnecessary quantum bits and the number of quantum gate operations, thereby increasing the algorithm's execution speed. On the other hand, leveraging the unconditional security provided by quantum encryption technology ensures a high level of confidentiality for data during transmission. This not only enhances the efficiency of information processing but also greatly improves the system's resilience to interference, maintaining high information fidelity even in noisy environments. Additionally, by simplifying quantum circuit design, it reduces the cost and technical complexity of hardware implementation, making large-scale commercial applications feasible.In practical applications, MicroAlgo's novel information hiding and transmission system has already been applied in multiple fields. For example, in medical image encryption, patient privacy data receives a higher level of protection; in financial transaction systems, customers' sensitive financial information is similarly safeguarded effectively. Through this approach, not only is information security enhanced, but processing efficiency is also improved, meeting the modern society's demand for high-speed and efficient data processing.
In the future, with continuous advancements in quantum computing and quantum encryption technologies, MicroAlgo's novel information hiding and transmission system is expected to expand beyond its current application scenarios to more emerging fields, such as artificial intelligence and big data analysis. For instance, in the field of artificial intelligence, leveraging the advantages of quantum computing can accelerate the training process of machine learning models; in big data analysis, quantum image processing technology can help extract valuable information from massive datasets more quickly. Through ongoing exploration and practice, quantum image processing technology will become more mature and refined, contributing to the construction of a more secure and efficient information society.
About MicroAlgo Inc.
MicroAlgo Inc. (the 'MicroAlgo'), a Cayman Islands exempted company, is dedicated to the development and application of bespoke central processing algorithms. MicroAlgo provides comprehensive solutions to customers by integrating central processing algorithms with software or hardware, or both, thereby helping them to increase the number of customers, improve end-user satisfaction, achieve direct cost savings, reduce power consumption, and achieve technical goals. The range of MicroAlgo's services includes algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence services. MicroAlgo's ability to efficiently deliver software and hardware optimization to customers through bespoke central processing algorithms serves as a driving force for MicroAlgo's long-term development.
Forward-Looking Statements
This press release contains statements that may constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions, many of which are beyond the control of MicroAlgo, including those set forth in the Risk Factors section of MicroAlgo's periodic reports on Forms 10-K and 8-K filed with the SEC. Copies are available on the SEC's website, www.sec.gov. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, MicroAlgo's expectations with respect to future performance and anticipated financial impacts of the business transaction.
MicroAlgo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as may be required by law.
Contact
MicroAlgo Inc.
Investor Relations
Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength
Honeywell International Inc. (NASDAQ:HON) is one of the best Dow stocks to invest in. On June 9, the company announced that it had finalized its $2.16 billion all-cash acquisition of Sundyne from private equity firm Warburg Pincus. Sundyne, known for its advanced pumps and gas compressors used in process industries, is expected to contribute immediately to Honeywell International Inc. (NASDAQ:HON)'s revenue growth, segment margins, and adjusted earnings per share during the first full year of ownership. Sundyne brings strong customer relationships and top-tier technology, which are expected to enhance Honeywell UOP's presence in areas like refining, petrochemicals, LNG, and clean energy. Integrated with the Honeywell Forge platform, the combined offering strengthens Honeywell's position in the energy transition by providing a comprehensive, scalable solution. This acquisition comes on the heels of Honeywell International Inc. (NASDAQ:HON)'s recent announcement to spin off its Aerospace Technologies and Solstice Advanced Materials units, moves aimed at creating three separate publicly traded companies, each with focused strategies and growth opportunities. Since December 2023, Honeywell has pursued several strategic initiatives to boost organic growth and streamline its operations, including $13.5 billion in value-enhancing acquisitions. The company operates globally across a wide range of industries. HON has surged by over 7% in the past 12 months. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
35 minutes ago
- Yahoo
How major US stock indexes fared Wednesday, 6/11/2025
Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China. On Wednesday: The S&P 500 fell 16.57 points, or 0.3%, to 6,022.24. The Dow Jones Industrial Average fell 1.10 points, or less than 0.1%, to 42,865.77. The Nasdaq composite fell 99.11 points, or 0.5%, to 19,615.88. The Russell 2000 index of smaller companies fell 8.17 points, or 0.4%, to 2,148.23. For the week: The S&P 500 is up 21.88 points, or 0.4%. The Dow is up 102.90 points, or 0.2%. The Nasdaq is up 85.92 points, or 0.4%. The Russell 2000 is up 15.99 points, or 0.7%. For the year: The S&P 500 is up 140.61 points, or 2.4%. The Dow is up 321.55 points, or 0.8%. The Nasdaq is up 305.08 points, or 1.6%. The Russell 2000 is down 81.92 points, or 3.7%. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
39 minutes ago
- Yahoo
Allarity Therapeutics Announces Changes to Board of Directors
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data